WO2020182229A1 - 一种融合蛋白及其制备利拉鲁肽中间体多肽的方法 - Google Patents

一种融合蛋白及其制备利拉鲁肽中间体多肽的方法 Download PDF

Info

Publication number
WO2020182229A1
WO2020182229A1 PCT/CN2020/088521 CN2020088521W WO2020182229A1 WO 2020182229 A1 WO2020182229 A1 WO 2020182229A1 CN 2020088521 W CN2020088521 W CN 2020088521W WO 2020182229 A1 WO2020182229 A1 WO 2020182229A1
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
seq
glp
pet
recombinant
Prior art date
Application number
PCT/CN2020/088521
Other languages
English (en)
French (fr)
Inventor
潘尚书
汤传根
李宬
刘晓锐
崔怀言
陈松
张昊宁
Original Assignee
美药星（南京）制药有限公司
南京汉欣医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美药星（南京）制药有限公司, 南京汉欣医药科技有限公司 filed Critical 美药星（南京）制药有限公司
Publication of WO2020182229A1 publication Critical patent/WO2020182229A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the invention relates to the technical field of genetic engineering and polypeptide preparation methods, in particular to a fusion protein and a method for preparing a liraglutide intermediate polypeptide.
  • Diabetes is due to the interaction of genetic and environmental factors, causing insufficient absolute or relative secretion of insulin and decreased sensitivity of target tissue cells to insulin, causing a series of metabolic disorder syndromes such as protein, fat, water and electrolytes, among which hyperglycemia is the main sign .
  • Typical clinical cases may have symptoms such as polyuria, polydipsia, polyphagia, weight loss, etc., that is, "three more and one less" symptoms.
  • type 1 diabetes patients accounted for 10%
  • type 2 diabetes patients accounted for 90%.
  • Liraglutide is a glucagon-like peptide (GLP-1) analog produced by genetic recombination technology, which has 97% sequence homology with natural human GLP-1 (7-37). Unlike natural GLP-1, the pharmacokinetic and pharmacodynamic properties of liraglutide in humans are more suitable for a once-a-day dosing regimen. After subcutaneous injection, it mainly prolongs the action time through the following mechanisms: one is to slow down the absorption through self-association, the other is to bind to albumin, and the third is to have higher enzyme stability to DPP-IV and NEP, thus Has a long plasma half-life.
  • GLP-1 glucagon-like peptide
  • Liraglutide is one of the representative drugs of glucagon peptide (GLP-1) analogues. In the United States and Europe, it is used as a second treatment for type 2 diabetic patients after metformin monotherapy or other anti-diabetic oral drugs failed. Third-line drug use. The 2013 edition of China's Type 2 Diabetes Prevention and Control Guidelines stipulated that glucagon (GLP-1) analogs should be used as third-line treatment drugs. Multiple clinical trials of liraglutide have proven that combining different oral hypoglycemic drugs can effectively control blood sugar, and can enable patients to lose weight, reduce systolic blood pressure and improve pancreatic ⁇ -cell function.
  • the molecular formula of liraglutide is C 172 H 265 N 43 O 51 and the molecular weight is 3751.20.
  • the 34th lysine Lys is changed to arginine Arg in the natural GLP-1 molecular structure.
  • Liraglutide was first developed by Novo Nordisk, and was obtained through genetic recombination technology using yeast production.
  • the synthesis method of the intermediate polypeptide GLP-1(7-37) in the prior art mainly adopts chemical synthesis.
  • the patent CN104045706B discloses the use of a large number of organic solvents, which is not friendly to the environment, and the steps are complicated and not conducive to large-scale industrial scale-up; There are many process impurities; the total yield is only 18%.
  • patent CN104745597A related to the biological preparation method discloses that the expression mode is intracellular soluble expression, and the expression amount is low, which is not conducive to industrial amplification.
  • Patent CN104592381A discloses that the dissolution of inclusion bodies takes too long, the volume is too large, and a large amount of urea is used; the inclusion bodies need to be refolded for a long time and the refolding protein concentration is 0.2g/L. The volume required for refolding is too large, which is not good for industry. enlarge.
  • the purpose of the present invention is to provide a fusion protein and a method for preparing liraglutide intermediate polypeptide GLP-1 (7-37), through gene recombination technology, using E. coli fermentation to induce expression to obtain Leading Peptide-DDDDK-GLP-1 (7-37) Fusion protein, in which Leading Peptide is used as the leader peptide of the fusion protein, which contributes to the high-level expression of the fusion protein and the renaturation of the liraglutide intermediate polypeptide;
  • DDDDK stands for aspartic acid-aspartic acid -Aspartic acid-Aspartic acid-Lysine, as the enterokinase recognition site, used to cut the Leading Peptide of the fusion protein;
  • GLP-1(7-37) represents the 7th position of the human glucagon-like peptide -37 amino acid sequence fragment (the 34th amino acid was mutated from Lys to Arg), which is the target protein sequence.
  • the above-mentioned fusion protein is subjected to operations such as dissolution, denaturation, restriction enzyme digestion, separation, etc. to obtain high yield and high purity polypeptide GLP-1 (7-37), which solves the problems of many impurities, low yield and use in the prior art.
  • a large number of organic reagents are not friendly to the environment. Intracellular soluble expression leads to low expression levels, long time for inclusion body dissolution and denaturation, and low protein concentration leads to excessive denaturation volume, which is not suitable for large-scale production and limits the increase in productivity. problem.
  • the present invention provides the following technical solution, a fusion protein Leading Peptide-DDDDK-GLP-1 (7-37) for the synthesis of liraglutide intermediate polypeptide GLP-1 (7-37), Leading Peptide is used as follows:
  • X 1 , X 2 is any one of P and Y amino acids
  • X 3 , X 4 and X 5 are any one of S, T and Y amino acids.
  • the leader peptide sequence was replaced with three amino acid residues (X 1 , X 2 and X 3 ) in the N-terminal part of the known SOD enzyme (MATHAVSVLKGDGX 1 VQGIINFEQHESNGX 2 VKVWGSIHGLX 3 EGLHGFHVH), and a segment of insulin B chain was added.
  • the analogue "KFVNQHLCGX 4 HLVALX 5 LV, where X 4 and X 5 are any one of S, T and Y” is designed to: 1. Facilitate the formation of inclusion bodies and increase the expression of the fusion protein; 2. , Facilitate the formation of alpha helix and refolding of liraglutide propeptide; 3. Balance the hydrophobicity and isoelectric point of the fusion protein, improve the purification effect, and perform one-step cationic purification before obtaining high purity and high yield liraglutide Peptide.
  • the C-terminus of the leader peptide sequence is connected to GLP-1 (7-37) liraglutide propeptide HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG (SEQ ID NO. 2) through the residue of DDDDK (SEQ ID NO.1).
  • the leader peptide sequence is one of SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, or SEQ ID NO. 8; specifically as follows:
  • the preferred leader peptide sequence is:
  • the present invention also provides a recombinant expression vector, which contains an encoding gene encoding the fusion protein.
  • the recombinant expression vector is obtained by inserting the coding gene clone into plasmid vectors pET-24a(+), pET-28a(+), pET-29a(+), pET-39b(+) Vector pET-24a(+)-Leading Peptide-DDDDK-GLP-1(7-37), pET-28a(+)-Leading Peptide-DDDDK-GLP-1(7-37), pET-29a(+)- Leading Peptide-DDDDK-GLP-1(7-37) or pET-39b(+)-Leading Peptide-DDDDK-GLP-1(7-37).
  • the present invention also provides a recombinant engineered bacteria containing the recombinant expression vector, which is obtained by transferring the recombinant expression vector into Escherichia coli, and the Escherichia coli includes JM109 (DE3), HMS174 (DE3), BL21 ( DE3) and Rostta2 (DE3) etc.
  • the invention also provides an application of the recombinant engineering bacteria in the expression of the recombinant liraglutide intermediate GLP-1 (7-37).
  • the present invention also provides a method for synthesizing liraglutide intermediate polypeptide GLP-1 (7-37) by using the encoding gene, which specifically includes the following steps: 1), synthesizing and encoding the aforementioned fusion protein Leading Peptide-DDDDK-GLP -1 (7-37) of the coding gene; 2). Connect the coding gene to the expression vector; 3). Transform the recombinant expression vector with the coding gene into E. coli to construct recombinant engineering bacteria; 4).
  • the method of connecting the encoding gene and the expression vector in the step 2) is: through HindIII/XhoI, HindIII/NcoI, XhoI/EagI or SacI/SalI and other enzymes
  • the cutting site is inserted into the corresponding restriction site of plasmid vector pET-24a(+), pET-28a(+), pET-29a(+) or pET-39b(+).
  • the recombinant engineered bacteria are fermented and cultured, and the inducer used for inducing expression is isopropylthiogalactoside (IPTG).
  • IPTG isopropylthiogalactoside
  • the washed inclusion bodies are added to the inclusion body solubilization buffer at a protein concentration of 5-40 g/L under alkaline conditions with a pH of 7.5-14 for dissolution change.
  • Refolding, reducing operating volume and reducing reagent cost; after dissolution, enzyme digestion can be carried out, and the refolding time is very short and less than 1h, which shortens the process time and improves the yield of GLP-1(7-37).
  • step 7) the specific method for the transformation, separation and purification by restriction enzyme digestion in step 7) is as follows: step 6) the denatured fusion protein is digested by enterokinase at 37°C for 8-12 hours. A mixture of intermediate polypeptides, tags, and linking peptides can be obtained, and the mixture can be separated by ion exchange to obtain intermediate polypeptide samples with the required purity.
  • a method for synthesizing the liraglutide intermediate polypeptide GLP-1 (7-37) by using the coding gene further specifically includes the following steps:
  • the washed inclusion bodies are added to the inclusion body solubilization buffer at a protein concentration of 20g/L under alkaline conditions of pH 7.5-14 , Dissolve for 1 hour to dissolve and denature the inclusion body, and then it can be digested by enzyme;
  • the HPLC purity of the purified liraglutide intermediate polypeptide can reach more than 92%, which is used for side chain modification.
  • the purified polypeptide has a molecular weight of 3383 Da identified by HPLC-MASS, which is the correct molecular weight of the liraglutide intermediate polypeptide.
  • the Leading Peptide-DDDDK-GLP-1 (7-37) fusion protein is constructed by changing the leader peptide sequence, and the expression mode is changed to the expression of intracellular insoluble inclusion bodies. Significant increase; (2) The inclusion bodies after washing are alkali-dissolved without using a large amount of denaturant.
  • Figure 1 is a construction diagram of the recombinant plasmid in Example 1.
  • Figure 2 is a construction diagram of the recombinant plasmid in Example 2.
  • Fig. 3 is a graph showing the growth curve of bacteria in the fermentation process in Example 7.
  • Example 4 is a diagram of cation purification of the mixed solution after restriction digestion in Example 13.
  • FIG. 5 is an HPLC chart of the ion exchange elution peak in Example 13.
  • Example 6 is a mass spectrum of the intermediate polypeptide in Example 13.
  • FIG. 7 is an HPLC chart of the ion exchange elution peak in Example 14.
  • Example 8 is an HPLC chart of the ion exchange elution peak in Example 15.
  • Fig. 9 is an HPLC chart of the ion exchange elution peak in Example 16.
  • FIG. 10 is an HPLC chart of the ion exchange elution peak in Example 17.
  • Example 11 is an HPLC chart of the ion exchange elution peak in Example 18.
  • the N-terminal leader peptide sequence can enhance expression and protect the liraglutide propeptide fusion protein from degradation by E. coli.
  • the preferred leader peptide sequence is MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLV (SEQ ID NO. 3).
  • the C-terminus of the leader peptide sequence is connected to the liraglutide propeptide through DDDDK residues, and the leader peptide is removed by enterokinase digestion. Therefore, the fusion protein Leading Peptide-DDDDK-GLP-1 (7-37) with the leading peptide SEQ ID NO. 3 has the full sequence of SEQ ID NO. 9, and the specific sequence is as follows:
  • the fusion protein Leading Peptide-DDDDK-GLP-1 (7-37) full sequence containing the leading peptide SEQ ID NO. 7 was sequentially designed.
  • the positive clone of the recombinant engineered bacteria obtained in Example 1 was inoculated into LB medium, cultured with shaking at 37° C. until the OD 600 value reached 2 as the seed solution, and then inserted into 6L of fermentation medium for cultivation.
  • the OD 600 value of the fermentation broth reaches 50
  • IPTG is added for induction, and it is put into the tank after induction for 10 hours. Centrifuge the cells to collect the bacteria after placing the tank.
  • Fig. 3 shows the growth curve of bacteria during the fermentation process.
  • the positive clones of the recombinant engineered bacteria obtained in Example 2 were inoculated in LB medium, cultured with shaking at 37° C. until the OD 600 value reached 2 as the seed solution, and inserted into 6L of fermentation medium for cultivation. When the OD 600 value of the fermentation broth reaches 50, IPTG is added for induction, and it is put into the tank after induction for 10 hours. Centrifuge the cells to collect the bacteria after placing the tank.
  • the positive clones of the recombinant engineered bacteria obtained in Example 3 were inoculated in LB medium, cultured with shaking at 37° C. until the OD 600 value reached 2 as the seed solution, and inserted into 6L of fermentation medium for cultivation. When the OD 600 value of the fermentation broth reaches 50, IPTG is added for induction, and it is put into the tank after induction for 10 hours. Centrifuge the cells to collect the bacteria after placing the tank.
  • the positive clones of the recombinant engineered bacteria obtained in Example 4 were inoculated in LB medium, cultured with shaking at 37° C. until the OD 600 value reached 2 as the seed solution, and inserted into 6L of fermentation medium for cultivation. When the OD 600 value of the fermentation broth reaches 50, IPTG is added for induction, and it is put into the tank after induction for 10 hours. Centrifuge the cells to collect the bacteria after placing the tank.
  • the positive clone of the recombinant engineered bacteria obtained in Example 5 was inoculated in LB medium, cultured with shaking at 37° C. until the OD 600 value reached 2 as the seed solution, and then inserted into 6L of fermentation medium for cultivation. When the OD 600 value of the fermentation broth reaches 50, IPTG is added for induction, and it is put into the tank after induction for 10 hours. Centrifuge the cells to collect the bacteria after placing the tank.
  • the positive clone of the recombinant engineered bacteria obtained in Example 6 was inoculated in LB medium, cultured with shaking at 37° C. until the OD 600 value reached 2 as the seed solution, and then inserted into 6L of fermentation medium for cultivation. When the OD 600 value of the fermentation broth reaches 50, IPTG is added for induction, and it is put into the tank after induction for 10 hours. Centrifuge the cells to collect the bacteria after placing the tank.
  • Example 7 After putting the fermentation broth obtained in Example 7 into the tank, the bacteria were collected by centrifugation, the breaking buffer was added according to the weight-volume ratio of 1:10, the bacteria were broken by a high-pressure homogenizer, and the inclusion body precipitate was collected by centrifugation. The precipitate was added to the washing buffer at a weight-volume ratio of 1:10, and the precipitate collected by centrifugation after washing was washed 3 times with the washing liquid. The washed inclusion bodies were added to the inclusion body dissolution buffer at a protein concentration of 20 g/L, and the pH was adjusted to alkaline dissolution for 1 hour for denaturation.
  • the dissolved inclusion body solution is added to enterokinase, and the mixture of intermediate polypeptide, tag and connecting peptide can be obtained after enzymatic hydrolysis at 37°C for 12 hours.
  • the ion-exchange purification obtains the washing peak 1, the washing peak 2, the target peak and the washing peak 3 in sequence.
  • the purity of the target protein with an elution time of 11.96min determined by HPLC is 95.1%.
  • the HPLC profile is shown in Figure 5.
  • the collected target protein is 22.9g, and the yield is 90.2%; Mass spectrometry detected that the molecular weight of the target protein was 3383.62 Da, which was consistent with the molecular weight of the liraglutide polypeptide intermediate, as shown in Figure 6.
  • Example 8 Put the fermentation broth obtained in Example 8 into the tank and collect the bacteria by centrifugation, add the crushing buffer solution according to the weight-volume ratio of 1:10, crush the bacteria by high pressure homogenization, and collect the inclusion body precipitate by centrifugation.
  • the precipitate was added to the washing buffer at a weight-volume ratio of 1:10, and the precipitate collected by centrifugation after washing was washed 3 times with the washing liquid.
  • the washed inclusion bodies were added to the inclusion body dissolution buffer at a protein concentration of 40 g/L, and the pH was adjusted to alkaline dissolution for 1 hour for denaturation.
  • the dissolved inclusion body solution is added to enterokinase, and after enzymatic hydrolysis at 37°C for 8 hours, a mixture of intermediate polypeptide, tag and connecting peptide can be obtained.
  • the mixture containing 27.6 g of the target protein was purified by ion exchange chromatography, and the elution peak sample was taken for HPLC and mass spectrometry detection.
  • the purity of the target protein detected by HPLC was 93.2%, as shown in Figure 7.
  • the collected target protein was 24.1.g, and the yield was 87.3%; mass spectrometry detected that the molecular weight of the target protein was consistent with the molecular weight of the liraglutide polypeptide intermediate.
  • Example 9 Put the fermentation broth obtained in Example 9 into the tank and collect the bacteria by centrifugation, add the crushing buffer solution according to the weight-volume ratio of 1:10, crush the bacteria by a high-pressure homogenizer, and collect the inclusion body precipitate by centrifugation.
  • the precipitate was added to the washing buffer at a weight-to-volume ratio of 1:10, and the precipitate collected by centrifugation was washed 3 times with the washing liquid.
  • the washed inclusion bodies were added to the inclusion body solubilization buffer at a protein concentration of 5 g/L, and the pH was adjusted to alkaline dissolution for 1 hour for denaturation.
  • the dissolved inclusion body solution is added to enterokinase, and the mixture of intermediate polypeptide, tag and connecting peptide can be obtained after enzymatic hydrolysis at 37°C for 12 hours.
  • the mixture containing 14.9g of the target protein was purified by ion exchange chromatography, and the elution peak sample was taken for HPLC and mass spectrometry.
  • the purity of the target protein was 94.5%.
  • the collected target protein was 13.2g.
  • the yield was 88.6%; mass spectrometry detected that the molecular weight of the target protein was consistent with that of the liraglutide polypeptide intermediate.
  • Example 10 Put the fermentation broth obtained in Example 10 into the tank and collect the bacteria by centrifugation, add the crushing buffer solution according to the weight-volume ratio of 1:10, crush the bacteria by a high-pressure homogenizer, and collect the inclusion body precipitate by centrifugation.
  • the precipitate was added to the washing buffer at a weight-to-volume ratio of 1:10, and the precipitate collected by centrifugation was washed 3 times with the washing liquid.
  • the washed inclusion bodies were added to the inclusion body solubilization buffer at a protein concentration of 10 g/L, and the pH was adjusted to alkaline dissolution for 1 hour for denaturation.
  • the dissolved inclusion body solution is added to enterokinase, and the mixture of intermediate polypeptide, tag and connecting peptide can be obtained after enzymatic hydrolysis at 37°C for 12 hours.
  • the mixture containing 13.8g of the target protein was purified by ion exchange chromatography, and the elution peak sample was taken for HPLC and mass spectrometry.
  • the purity of the target protein was 92.2%.
  • the collected target protein was 12.1g.
  • the yield was 87.7%; mass spectrometry detected that the molecular weight of the target protein was consistent with the molecular weight of the liraglutide polypeptide intermediate.
  • Example 11 After putting the fermentation broth obtained in Example 11 into the tank, the bacteria were collected by centrifugation, the breaking buffer was added according to the weight-volume ratio of 1:10, the bacteria were broken by a high-pressure homogenizer, and the inclusion body precipitate was collected by centrifugation. The precipitate was added to the washing buffer at a weight-to-volume ratio of 1:10, and the precipitate collected by centrifugation was washed 3 times with the washing liquid. The washed inclusion bodies were added to the inclusion body dissolution buffer at a protein concentration of 20 g/L, and the pH was adjusted to alkaline dissolution for 1 hour for denaturation.
  • the dissolved inclusion body solution is added to enterokinase, and the mixture of intermediate polypeptide, tag and connecting peptide can be obtained after enzymatic hydrolysis at 37°C for 12 hours.
  • the mixture containing 15.6g of the target protein was purified by ion exchange chromatography, and the elution peak sample was taken for HPLC and mass spectrometry.
  • the purity of the target protein was 93.5%.
  • the collected target protein was 13.6g.
  • the yield was 87.2%; mass spectrometry detected that the molecular weight of the target protein was consistent with the molecular weight of the liraglutide polypeptide intermediate.
  • Example 12 After putting the fermentation broth obtained in Example 12 into the tank, the bacteria were collected by centrifugation, the breaking buffer was added according to the weight-volume ratio of 1:10, the bacteria were broken by a high-pressure homogenizer, and the inclusion body precipitate was collected by centrifugation. The precipitate was added to the washing buffer at a weight-to-volume ratio of 1:10, and the precipitate collected by centrifugation was washed 3 times with the washing liquid. The washed inclusion bodies were added to the inclusion body dissolution buffer at a protein concentration of 40 g/L, and the pH was adjusted to alkaline dissolution for 1 hour for denaturation.
  • the dissolved inclusion body solution is added to enterokinase, and the mixture of intermediate polypeptide, tag and connecting peptide can be obtained after enzymatic hydrolysis at 37°C for 12 hours.
  • the mixture containing 12.4g of target protein was purified by ion exchange chromatography, and the elution peak sample was taken for HPLC and mass spectrometry.
  • the purity of the target protein was 93.9%.
  • the collected target protein was 11.0g.
  • the yield was 88.7%; mass spectrometry detected that the molecular weight of the target protein was consistent with the molecular weight of the liraglutide polypeptide intermediate.

Abstract

提供一种融合蛋白Leading Peptide-DDDDK-GLP-1(7-37)及用其制备利拉鲁肽中间体多肽GLP-1(7-37)的方法。制备方法包括构建表达融合蛋白的工程菌，通过培养，诱导胞内不溶性包涵体形式的融合蛋白的表达，再经过变性、复性、酶切和分离纯化得到中间体多肽GLP-1(7-37)。融合蛋白的前导肽序列可以使融合蛋白的表达方式变为胞内不溶性包涵体表达，表达量显著增加，洗涤后的包涵体采用高pH溶解，无需使用大量的变性剂，变复性时间不超过1h，减少复性工序，缩小酶切体系，降低化学试剂成本，分离度高，有利于工业化放大。

Description

一种融合蛋白及其制备利拉鲁肽中间体多肽的方法 技术领域
本发明涉及基因工程及多肽制备方法技术领域，具体涉及一种融合蛋白及其制备利拉鲁肽中间体多肽的方法。
背景技术
糖尿病是由于遗传和环境因素相互作用，引起胰岛素绝对或相对分泌不足以及靶组织细胞对胰岛素敏感性降低，引起蛋白质、脂肪、水和电解质等一系列代谢紊乱综合征，其中以高血糖为主要标志。临床典型病例可出现多尿、多饮、多食、消瘦等表现，即“三多一少”症状。而近年来，随着生活水平的提高，饮食结构变化，大多数人动少坐多等因素，导致全球糖尿病发病率增长迅速。其中，1型糖尿病患者占10％，2型糖尿病患者占90％。
利拉鲁肽(Liraglutide)是一种通过基因重组技术生产的胰高血糖素样肽(GLP-1)类似物，与天然人GLP-1(7-37)具有97％的序列同源性，与天然的GLP-1不同的是，利拉鲁肽在人体中的药代动力学和药效动力学特性更适用于每天1次的给药方案。皮下注射给药后，其主要通过如下机理延长作用时间：一是通过自联作用使吸收减慢，二是与白蛋白结合，三是对DPP-Ⅳ和NEP具有更高的酶稳定性，从而具有较长的血浆半衰期。在2型糖尿病患者中，单次给予利拉鲁肽可以观察到胰岛素分泌率以葡萄糖浓度依赖的模式增加。目前国内利拉鲁肽完全依赖进口，价格昂贵，因此迫切需要提供一种利拉鲁肽的制备方法，为广大糖尿病患者带来福音。
利拉鲁肽作为胰高血糖素肽(GLP-1)类似物的代表药物之一，在美国和欧洲地区，它作为2型糖尿病患者经二甲双胍单药或其他抗糖尿病口服药物治疗失败后的二三线药物使用。2013年版中国2型糖尿病防治指南中规定将胰高血糖素(GLP-1)类似物作为三线治疗药物使用。利拉鲁肽的多个临床试验研究已经证明联合不同的口服降糖药可以有效控制血糖，并能够使患者减轻体重、减少收缩压及改善胰岛β细胞功能。
利拉鲁肽结构式如下：
NH 2-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-(N-ε-(N-α-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-COOH
由以上结构式可知：利拉鲁肽分子式为C 172H 265N 43O 51，分子量为3751.20，是在天然GLP-1分子结构上将第34位的赖氨酸Lys改为精氨酸Arg，并在26位增加了1条16碳棕榈脂肪酸(N-ε-(γ-Glu(N-α-十六酰基)))侧链而得到的衍生物。
利拉鲁肽最早由诺和诺德公司开发研制，通过基因重组技术，利用酵母生产获得。现有技术中中间体多肽GLP-1(7-37)的合成方法主要采用化学合成，如专利CN104045706B公开了使用多种大量有机溶剂，对于环境不友好，且步骤繁琐不利于大规模工业放大；工艺杂质多；总收率仅18％。
另外涉及生物制备方法的专利CN104745597A中公开了表达方式为胞内可溶性表达，表达量较低，不利于工业化放大。专利CN104592381A中公开了包涵体溶解耗时过长，体积过大，使用大量的尿素；包涵体需要长时间复性并且复性蛋白浓度0.2g/L，复性所需体积过大，不利于工业放大。
发明内容：
本发明的目的在于提供一种融合蛋白和制备利拉鲁肽中间体多肽GLP-1(7-37)的方法，通过基因重组技术，利用大肠杆菌发酵诱导表达获得Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白，其中Leading Peptide作为融合蛋白的前导肽，有助于融合蛋白的高水平表达和利拉鲁肽中间体多肽的复性；DDDDK表示天冬氨酸-天冬氨酸-天冬氨酸-天冬氨酸-赖氨酸，作为肠激酶识别位点，用于切除融合蛋白的Leading Peptide；GLP-1(7-37)表示人胰高血糖素样肽的7位-37位氨基酸序列片段(第34位氨基酸由Lys突变为Arg)，是目的蛋白序列。上述融合蛋白经过溶解、变复性、酶切、分离等操作获得高收率和高纯度的多肽GLP-1(7-37)，解决了现有技术中存在的杂质多、收率低、使用大量有机试剂对环境不友好，胞内可溶性表达导致表达量低，包涵体溶解和变复性时间长，蛋白浓度低导致变复性体积过大，不适合大规模生产，并限制了产能提升的问题。
为了实现上述目的，本发明提供如下的技术方案，一种用于合成利拉鲁肽中间体多肽GLP-1(7-37)的融合蛋白Leading Peptide-DDDDK-GLP-1(7-37)，采用如下前导肽Leading Peptide：
MATHAVSVLKGDGX 1VQGIINFEQHESNGX 2VKVWGSIHGLX 3EGLHGFHVHKFVNQHLCGX 4HLVALX 5LV，
X 1，X 2：为P和Y中的任何一个氨基酸；
X 3，X 4和X 5：为S，T和Y中的任何一个氨基酸。
该前导肽序列在已知的SOD酶的N末端部分(MATHAVSVLKGDGX 1VQGIINFEQHESNGX 2VKVWGSIHGLX 3EGLHGFHVH)进行三个氨基酸残基的置换(X 1、X 2和X 3)，并且添加了一段胰岛素B链片段类似物“KFVNQHLCGX 4HLVALX 5LV，其中X 4和X 5：为S,T和Y中的任何一个氨基酸”，设计的 目的在于：1、有利于包涵体形成，提高融合蛋白的表达量；2、利于利拉鲁肽前肽形成α螺旋进而复性；3、平衡融合蛋白的疏水性和等电点，提高纯化的效果，进行一步阳离子纯化得到高纯度和高收率的利拉鲁肽前肽。
该前导肽序列的C端通过DDDDK(SEQ ID NO.1)残基连接到GLP-1(7-37)利拉鲁肽前肽HAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG(SEQ ID NO.2)上。
具体实施例中，前导肽序列是SEQ ID NO.3、SEQ ID NO.4、SEQ ID NO.5、SEQ ID NO.6、SEQ ID NO.7或SEQ ID NO.8中的一种；具体如下：
MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLV(SEQ ID NO.3)；
MATHAVSVLKGDGPVQGIINFEQHESNGYVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLV(SEQ ID NO.4)；
MATHAVSVLKGDGYVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLV(SEQ ID NO.5)；
MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGTHLVALTLV(SEQ ID NO.6)；
MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLSEGLHGFHVHKFVNQHLCGSHLVALSLV(SEQ ID NO.7)；
MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLYEGLHGFHVHKFVNQHLCGYHLVALYLV(SEQ ID NO.8)。
其中优选的前导肽序列为：
MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLV(SEQ ID NO.3)。
本发明还提供了一种重组表达载体，包含编码所述融合蛋白的编码基因。
作为优选，所述重组表达载体，通过将所述编码基因克隆插入质粒载体pET-24a(+)、pET-28a(+)、pET-29a(+)、pET-39b(+)中获得重组表达载体pET-24a(+)-Leading Peptide-DDDDK-GLP-1(7-37)、pET-28a(+)-Leading Peptide-DDDDK-GLP-1(7-37)、pET-29a(+)-Leading Peptide-DDDDK-GLP-1(7-37)或pET-39b(+)-Leading Peptide-DDDDK-GLP-1(7-37)。
本发明还提供了一种包含所述重组表达载体的重组工程菌，采用所述的重组表达载体转入到大肠杆菌中得到，所述大肠杆菌包括JM109(DE3)、HMS174(DE3)、BL21(DE3)和Rostta2(DE3)等。
本发明还提供了一种所述重组工程菌在重组利拉鲁肽中间体GLP-1(7-37)表达方面的应用。
本发明还提供了一种利用所述编码基因合成利拉鲁肽中间体多肽GLP-1(7-37)的方法，具体包括以下步骤：1)、合成编码上述融合蛋白Leading Peptide-DDDDK-GLP-1(7-37)的编码基因；2)、将编码基因连接到表达载体中；3)、将带有编码基因的重组表达载体转化到大肠杆菌中，构建重组工程菌；4)、利用抗性平板筛选含有目的基因质粒的重组工程菌；5)、重组工程菌发酵，诱导胞内不溶性包涵体形式的融合蛋白的表达，表达量高；6)、将收集后的菌体进行细胞高压均质破碎，收集包涵体、然后将包涵体经过洗涤和变复性；7)、酶切转化、分离纯化获得中间体多肽GLP-1(7-37)。
作为本发明的进一步改进，所述的步骤2)中编码基因与表达载体的连接方式为：通过Hind III/Xho I、Hind III/Nco I、Xho I/Eag I或者Sac I/Sal I等酶切位点插入到质粒载体pET-24a(+)、pET-28a(+)、pET-29a(+)或pET-39b(+)相应酶切位点中。
作为本发明的进一步改进，所述步骤5)中重组工程菌进行发酵培养，诱导表达所用的诱导剂为异丙基硫代半乳糖苷(IPTG)。
作为本发明的进一步改进，所述步骤6)中将洗涤后的包涵体在pH为7.5-14的碱性条件下，按照蛋白浓度为5-40g/L加入包涵体溶解缓冲液，进行溶解变复性，缩小操作体积，降低试剂成本；溶解后就可以进行酶切，变复性时间很短不超过1h，缩短工艺时间，提高GLP-1(7-37)的收率。
作为本发明的进一步改进，所述步骤7)中所述酶切转化、分离纯化的具体方式为：步骤6)变复性后的融合蛋白经肠激酶在37℃下酶解8-12h后即可得到中间体多肽、标签和连接肽的混合液，混合液使用离子交换分离即可获得纯度符合要求的中间体多肽样品。
作为本发明的进一步改进，一种利用所述编码基因合成利拉鲁肽中间体多肽GLP-1(7-37)的方法，还具体包括以下步骤：
1)合成编码基因，所述编码基因编码权利要求1所述的融合蛋白，所述融合蛋白包含SEQ ID NO.3所示的前导肽序列，所述融合蛋白的氨基酸序列为SEQ ID NO.9，具体序列如下所示：
MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLVDDDDKHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG；
2)将编码基因通过Hind III/Xho I酶切位点连接到表达载体质粒pET-24a(+)中；
3)将带有编码基因的重组表达载体转化到大肠杆菌JM109(DE3)宿主中，构建重组工程菌；
4)利用抗性平板筛选含有目的基因质粒的重组工程菌；
5)重组工程菌发酵，诱导胞内不溶性包涵体形式的融合蛋白的表达；
6)将菌体进行高压均质，收集包涵体，然后将包涵体洗涤，洗涤后的包涵体在pH为7.5-14 的碱性条件下，按照蛋白浓度为20g/L加入包涵体溶解缓冲液，溶解1h进行包涵体溶解变性和变复性，溶解后既可以酶切；
7)酶切转化和分离纯化得到中间体多肽GLP-1(7-37)。
纯化后的利拉鲁肽中间体多肽HPLC纯度可以达到92％以上，用于侧链的修饰。纯化后的多肽经HPLC-MASS鉴定分子量为3383Da，为正确的利拉鲁肽中间体多肽的分子量。
本发明相对现有技术，具有以下优势：(1)通过改变前导肽序列，构建Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白，表达方式变为胞内不溶性包涵体表达，表达量显著增加；(2)洗涤后的包涵体采用碱溶，无需使用大量的变性剂，按照蛋白浓度为5-40g/L的高浓度加入包涵体溶解缓冲液，变复性时间大大缩短不超过1h，溶解后既可以酶切，肠激酶酶解时间大大缩短；减少复性工序，缩小酶切体系，降低化学试剂成本，有利于工业化放大；(3)采用离子交换分离纯化，分离度高，纯化效果好，杂质少，操作简单。本发明制备的利拉鲁肽中间体多肽纯度达到92％以上，收率大于87％。
附图说明
图1是实施例1中重组质粒的构建图。
图2是实施例2中重组质粒的构建图。
图3是实施例7中发酵过程中菌体生长曲线图。
图4是实施例13中酶切后混合液阳离子纯化图。
图5是实施例13中离子交换洗脱峰的HPLC谱图。
图6是实施例13中中间体多肽质谱图。
图7是实施例14中离子交换洗脱峰的HPLC谱图。
图8是实施例15中离子交换洗脱峰的HPLC谱图。
图9是实施例16中离子交换洗脱峰的HPLC谱图。
图10是实施例17中离子交换洗脱峰的HPLC谱图。
图11是实施例18中离子交换洗脱峰的HPLC谱图。
具体实施例方式
为便于本领域技术人员理解本发明内容，下面将结合具体实施例进一步描述本发明的技术方案，但以下内容不应以任何方式限制本发明权利要求书请求保护的范围。
下述实施例中所用的材料、试剂等，如无特殊说明，均可从商业途径得到。
实施例1 重组工程菌的构建
设计一个用于在大肠杆菌中表达的利拉鲁肽前肽的融合蛋白序列。N端前导肽序列可以增强表达，保护利拉鲁肽前肽融合蛋白，防止被大肠杆菌降解。优选的前导肽序列是MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLV(SEQ ID NO.3)。该前导肽序列的C端通过DDDDK残基连接到利拉鲁肽前肽上，前导肽通过肠激酶酶切去除。因此带前导肽SEQ ID NO.3的融合蛋白Leading Peptide-DDDDK-GLP-1(7-37)全序列为SEQ ID NO.9，具体序列如下所示：
MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLVDDDDKHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG；
利用融合PCR技术合成上述的Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白的基因片段，将获得的序列cDNA通过Hind III/Nco I酶切位点插入到质粒pET-28a(+)相应酶切位点中，构建成的重组质粒如图1所示，插入编码Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白基因的重组质粒通过常规基因工程技术转入到宿主大肠杆菌BL21(DE3)中。
实施例2 重组工程菌的构建
参考与实施例1同样的方法设计包含前导肽SEQ ID NO.4的融合蛋白Leading Peptide-DDDDK-GLP-1(7-37)全序列。
利用常规的融合PCR技术合成上述的Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白的基因，将获得的序列cDNA通过Hind III/Xho I酶切位点插入到质粒pET-24a(+)相应酶切位点中，构建成的重组质粒如图2所示，插入编码Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白基因的重组质粒通过常规的基因工程技术转入到宿主大肠杆菌HMS174(DE3)中。
实施例3 重组工程菌的构建
参考与实施例1同样的方法依次设计包含前导肽SEQ ID NO.5的融合蛋白Leading Peptide-DDDDK-GLP-1(7-37)全序列。
利用常规的融合PCR技术合成上述的Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白的基因，将获得的序列cDNA通过Xho I/Eag I酶切位点插入到质粒pET-29a(+)相应酶切位点中，插入编码Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白基因的重组质粒通过常规的基因工程技术转入到宿主大肠杆菌JM109(DE3)中。
实施例4 重组工程菌的构建
参考与实施例1同样的方法依次设计包含前导肽SEQ ID NO.6的融合蛋白Leading Peptide-DDDDK-GLP-1(7-37)全序列。
利用常规的融合PCR技术合成上述的Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白的基因，将获得的序列cDNA通过Sac I/Sal I酶切位点插入到质粒pET-39(b)相应酶切位点中，插入编码Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白基因的重组质粒通过常规的基因工程技术转入到宿主大肠杆菌Rosetta 2(DE3)中。
实施例5 重组工程菌的构建
参考与实施例1同样的方法依次设计包含前导肽SEQ ID NO.7的融合蛋白Leading Peptide-DDDDK-GLP-1(7-37)全序列。利用常规的融合PCR技术合成上述的Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白的基因，将获得的序列cDNA通过Hind III/Xho I酶切位点插入到质粒pET-24a(+)相应酶切位点中，插入编码Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白基因的重组质粒通过常规的基因工程技术转入到宿主大肠杆菌JM109(DE3)中。
实施例6 重组工程菌的构建
参考与实施例1同样的方法依次设计包含前导肽SEQ ID NO.8的融合蛋白Leading Peptide-DDDDK-GLP-1(7-37)全序列。
利用常规的融合PCR合成上述的Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白的基因，将获得的序列cDNA通过Hind III/Xho I酶切位点插入到质粒pET-24a(+)相应酶切位点中，插入编码Leading Peptide-DDDDK-GLP-1(7-37)融合蛋白基因的重组质粒通过常规的基因工程技术转入到宿主大肠杆菌JM109(DE3)中。
实施例7 工程菌发酵培养
接种实施例1所得的重组工程菌阳性克隆于LB培养基中，在37℃振荡培养至OD 600值达到2时作为种子液，接入6L的发酵培养基中进行培养。当发酵液OD 600值达到50时加入IPTG进行诱导，诱导10h后放罐。放罐后离心收集菌体。发酵过程中菌体生长曲线图如图3所示。
实施例8 工程菌发酵培养
接种实施例2所得的重组工程菌阳性克隆于LB培养基中，在37℃振荡培养至OD 600值达到2时作为种子液，接入6L的发酵培养基中进行培养。当发酵液OD 600值达到50时加入 IPTG进行诱导，诱导10h后放罐。放罐后离心收集菌体。
实施例9 工程菌发酵培养
接种实施例3所得的重组工程菌阳性克隆于LB培养基中，在37℃振荡培养至OD 600值达到2时作为种子液，接入6L的发酵培养基中进行培养。当发酵液OD 600值达到50时加入IPTG进行诱导，诱导10h后放罐。放罐后离心收集菌体。
实施例10 工程菌发酵培养
接种实施例4所得的重组工程菌阳性克隆于LB培养基中，在37℃振荡培养至OD 600值达到2时作为种子液，接入6L的发酵培养基中进行培养。当发酵液OD 600值达到50时加入IPTG进行诱导，诱导10h后放罐。放罐后离心收集菌体。
实施例11 工程菌发酵培养
接种实施例5所得的重组工程菌阳性克隆于LB培养基中，在37℃振荡培养至OD 600值达到2时作为种子液，接入6L的发酵培养基中进行培养。当发酵液OD 600值达到50时加入IPTG进行诱导，诱导10h后放罐。放罐后离心收集菌体。
实施例12 工程菌发酵培养
接种实施例6所得的重组工程菌阳性克隆于LB培养基中，在37℃振荡培养至OD 600值达到2时作为种子液，接入6L的发酵培养基中进行培养。当发酵液OD 600值达到50时加入IPTG进行诱导，诱导10h后放罐。放罐后离心收集菌体。
实施例13 中间体多肽的纯化(最佳实施例)
将实施例7所得的发酵液放罐后离心收集菌体，按照重量体积比1:10加入破碎缓冲液，通过高压均质机破碎菌体，离心收集包涵体沉淀。将沉淀按重量体积比1:10加入洗涤缓冲液，洗涤后离心收集的沉淀用洗涤液洗涤3次。将洗涤后的包涵体按照蛋白浓度为20g/L加入包涵体溶解缓冲液，调节pH为碱性溶解1h进行变复性。溶解后的包涵体溶液加入肠激酶，在37℃下酶解12h后即可得到中间体多肽、标签和连接肽的混合液。取含25.4g目的蛋白的混合液，使用离子交换纯化后获得纯度为95.1％的中间体多肽样品。如图4所示，离子交换纯化依次得到洗杂峰1、洗杂峰2、目的峰和洗杂峰3。取目的峰样品进行HPLC和质谱检测，HPLC检测洗脱时间为11.96min的目的蛋白的纯度为95.1％，HPLC图谱如图5所示，收集到的目的蛋白为22.9g，收率为90.2％；质谱检测出目的蛋白的分子量为3383.62Da，和利拉 鲁肽多肽中间体分子量一致，如图6所示。
实施例14 中间体多肽的纯化
将实施例8所得的发酵液放罐后离心收集菌体，按照重量体积比1:10加入破碎缓冲液，通过高压均质破碎菌体，离心收集包涵体沉淀。将沉淀按重量体积比1:10加入洗涤缓冲液，洗涤后离心收集的沉淀用洗涤液洗涤3次。将洗涤后的包涵体按照蛋白浓度为40g/L加入包涵体溶解缓冲液，调节pH为碱性溶解1h进行变复性。溶解后的包涵体溶液加入肠激酶，在37℃下酶解8h后即可得到中间体多肽、标签和连接肽的混合液。取含27.6g目的蛋白的混合液进行离子交换层析纯化，取洗脱峰样品进行HPLC和质谱检测，HPLC检测目的蛋白的纯度为93.2％，如图7所示。收集到的目的蛋白为24.1.g，收率为87.3％；质谱检测出目的蛋白的分子量和利拉鲁肽多肽中间体分子量一致。
实施例15 中间体多肽的纯化
将实施例9所得的发酵液放罐后离心收集菌体，按照重量体积比1:10加入破碎缓冲液，通过高压均质机破碎菌体，离心收集包涵体沉淀。将沉淀按重量体积比1:10加入洗涤缓冲液，离心收集的沉淀用洗涤液洗涤3次。将洗涤后的包涵体按照蛋白浓度为5g/L加入包涵体溶解缓冲液，调节pH为碱性溶解1h进行变复性。溶解后的包涵体溶液加入肠激酶，在37℃下酶解12h后即可得到中间体多肽、标签和连接肽的混合液。取含14.9g目的蛋白的混合液进行离子交换层析纯化，取洗脱峰样品进行HPLC和质谱检测，目的蛋白的纯度为94.5％，如图8所示，收集到的目的蛋白为13.2g，收率为88.6％；质谱检测出目的蛋白的分子量与利拉鲁肽多肽中间体分子量一致。
实施例16 中间体多肽的纯化
将实施例10所得的发酵液放罐后离心收集菌体，按照重量体积比1:10加入破碎缓冲液，通过高压均质机破碎菌体，离心收集包涵体沉淀。将沉淀按重量体积比1:10加入洗涤缓冲液，离心收集的沉淀用洗涤液洗涤3次。将洗涤后的包涵体按照蛋白浓度为10g/L加入包涵体溶解缓冲液，调节pH为碱性溶解1h进行变复性。溶解后的包涵体溶液加入肠激酶，在37℃下酶解12h后即可得到中间体多肽、标签和连接肽的混合液。取含13.8g目的蛋白的混合液进行离子交换层析纯化，取洗脱峰样品进行HPLC和质谱检测，目的蛋白的纯度为92.2％，如图9所示，收集到的目的蛋白为12.1g，收率为87.7％；质谱检测出目的蛋白的分子量与利拉鲁肽多肽中间体分子量一致。
实施例17 中间体多肽的纯化
将实施例11所得的发酵液放罐后离心收集菌体，按照重量体积比1:10加入破碎缓冲液，通过高压均质机破碎菌体，离心收集包涵体沉淀。将沉淀按重量体积比1:10加入洗涤缓冲液，离心收集的沉淀用洗涤液洗涤3次。将洗涤后的包涵体按照蛋白浓度为20g/L加入包涵体溶解缓冲液，调节pH为碱性溶解1h进行变复性。溶解后的包涵体溶液加入肠激酶，在37℃下酶解12h后即可得到中间体多肽、标签和连接肽的混合液。取含15.6g目的蛋白的混合液进行离子交换层析纯化，取洗脱峰样品进行HPLC和质谱检测，目的蛋白的纯度为93.5％，如图10所示，收集到的目的蛋白为13.6g，收率为87.2％；质谱检测出目的蛋白的分子量与利拉鲁肽多肽中间体分子量一致。
实施例18 中间体多肽的纯化
将实施例12所得的发酵液放罐后离心收集菌体，按照重量体积比1:10加入破碎缓冲液，通过高压均质机破碎菌体，离心收集包涵体沉淀。将沉淀按重量体积比1:10加入洗涤缓冲液，离心收集的沉淀用洗涤液洗涤3次。将洗涤后的包涵体按照蛋白浓度为40g/L加入包涵体溶解缓冲液，调节pH为碱性溶解1h进行变复性。溶解后的包涵体溶液加入肠激酶，在37℃下酶解12h后即可得到中间体多肽、标签和连接肽的混合液。取含12.4g目的蛋白的混合液进行离子交换层析纯化，取洗脱峰样品进行HPLC和质谱检测，目的蛋白的纯度为93.9％，如图11所示，收集到的目的蛋白为11.0g，收率为88.7％；质谱检测出目的蛋白的分子量与利拉鲁肽多肽中间体分子量一致。

Claims (10)

  1. 一种融合蛋白，其特征在于：所述融合蛋白为Leading Peptide-DDDDK-GLP-1(7-37)，在利拉鲁肽中间体制备中，采用如下前导肽Leading Peptide：
    MATHAVSVLKGDGX 1VQGIINFEQHESNGX 2VKVWGSIHGLX 3EGLHGFHVHKFVNQHLCGX 4HLVALX 5LV，
    X 1,X 2：为P和Y中的任何一个氨基酸；
    X 3,X 4和X 5：为S,T和Y中的任何一个氨基酸。
  2. 根据权利要求1所述的融合蛋白，其特征在于：所述的前导肽序列是SEQ ID NO.3、SEQ ID NO.4、SEQ ID NO.5、SEQ ID NO.6、SEQ ID NO.7或SEQ ID NO.8中的一种；
    SEQ ID NO.3序列为：
    MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLV；
    SEQ ID NO.4序列为：
    MATHAVSVLKGDGPVQGIINFEQHESNGYVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLV；
    SEQ ID NO.5序列为：
    MATHAVSVLKGDGYVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLV；
    SEQ ID NO.6序列为：
    MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGTHLVALTLV；
    SEQ ID NO.7序列为：
    MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLSEGLHGFHVHKFVNQHLCGSHLVALSLV；
    SEQ ID NO.8序列为：
    MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLYEGLHGFHVHKFVNQHLCGYHLVALYLV。
  3. 根据权利要求2所述的融合蛋白，其特征在于：所述的前导肽序列是SEQ ID NO.3，具体序列为：
    MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLV。
  4. 一种重组表达载体，其特征在于：含有编码权利要求1所述融合蛋白的编码基因。
  5. 根据权利要求4所述的重组表达载体，其特征在于：通过将所述的编码基因克隆进入质粒载体pET-24a(+)、pET-28a(+)、pET-29a(+)或者pET-39b(+)中获得重组表达载体pET-24a(+)-Leading Peptide-DDDDK-GLP-1(7-37)、pET-28a(+)-Leading Peptide-DDDDK-GLP-1(7-37)、pET-29a(+)-Leading Peptide-DDDDK-GLP-1(7-37)或pET-39b(+)-Leading Peptide-DDDDK-GLP-1(7-37)。
  6. 一种包含权利要求5所述的重组表达载体的重组工程菌，其特征在于：采用所述的重组表达载体转入到大肠杆菌JM109(DE3)、HMS174(DE3)、BL21(DE3)和Rosetta 2(DE3)中任意一种得到。
  7. 一种权利要求6所述的重组工程菌在重组利拉鲁肽中间体GLP-1(7-37)表达方面的应用。
  8. 一种利拉鲁肽中间体GLP-1(7-37)的制备方法，其特征在于，包括以下步骤：
    1)合成编码基因，所述编码基因编码权利要求1～3任一项所述的融合蛋白；
    2)将编码基因连接到表达载体中；
    3)将带有编码基因的重组表达载体转化到大肠杆菌宿主中，构建重组工程菌；
    4)利用抗性平板筛选含有目的基因质粒的重组工程菌；
    5)重组工程菌发酵，诱导胞内不溶性包涵体形式的融合蛋白的表达；
    6)将菌体进行高压均质，收集包涵体，然后将包涵体经过洗涤和变复性；
    7)酶切转化和分离纯化得到中间体多肽GLP-1(7-37)。
  9. 根据权利要求8所述的制备方法，其特征在于：
    所述的步骤2)中编码基因与表达载体的连接方式为通过Hind III/Xho I、Hind III/Nco I、Xho I/Eag I或者Sac I/Sal I酶切位点插入到质粒载体pET-24a(+)、pET-28a(+)、pET-29a(+)或者pET-39(b)中的任意一种相应酶切位点中；
    所述步骤5)中重组工程菌进行发酵培养，诱导表达所用的诱导剂为异丙基硫代半乳糖苷；
    所述步骤6)中将洗涤后的包涵体在pH为7.5-14的碱性条件下，按照蛋白浓度为5-40g/L加入包涵体溶解缓冲液，进行包涵体溶解变性；
    所述步骤7)中所述酶切转化、分离纯化的具体方式为：步骤6)变复性后的融合蛋白经肠激酶酶解8-12h后即可得到中间体多肽、标签和连接肽的混合液，混合液使用离子交换分离即可获得纯度符合要求的中间体多肽样品。
  10. 根据权利要求8所述的制备方法，其特征在于：
    1)合成编码基因，所述编码基因编码权利要求1所述的融合蛋白，所述融合蛋白包含SEQ ID NO.3所示的氨基酸序列，所述融合蛋白的氨基酸序列为SEQ ID NO.9，具体序列如下所示：
    MATHAVSVLKGDGPVQGIINFEQHESNGPVKVWGSIHGLTEGLHGFHVHKFVNQHLCGSHLVALYLVDDDDKHAEGTFTSDVSSYLEGQAAKEFIAWLVRGRG；
    2)将编码基因通过Hind III/Xho I酶切位点连接到表达载体质粒pET-24a(+)中；
    3)将带有编码基因的重组表达载体转化到大肠杆菌JM109(DE3)宿主中，构建重组工程菌；
    4)利用抗性平板筛选含有目的基因质粒的重组工程菌；
    5)重组工程菌发酵，诱导胞内不溶性包涵体形式的融合蛋白的表达；
    6)将菌体进行高压均质，收集包涵体，然后将包涵体洗涤，洗涤后的包涵体在pH为7.5-14的碱性条件下，按照蛋白浓度为20g/L加入包涵体溶解缓冲液，溶解1h进行包涵体溶解变性和变复性，溶解后既可以酶切；
    7)酶切转化和分离纯化得到中间体多肽GLP-1(7-37)。
PCT/CN2020/088521 2019-03-14 2020-04-30 一种融合蛋白及其制备利拉鲁肽中间体多肽的方法 WO2020182229A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201910195438.2 2019-03-14
CN201910195438.2A CN109879970A (zh) 2019-03-14 2019-03-14 一种融合蛋白及其制备利拉鲁肽中间体多肽的方法
CN201910515446.0 2019-06-14
CN201910515446.0A CN110128552B (zh) 2019-03-14 2019-06-14 一种融合蛋白及其制备利拉鲁肽中间体多肽的方法

Publications (1)

Publication Number Publication Date
WO2020182229A1 true WO2020182229A1 (zh) 2020-09-17

Family

ID=66932475

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/088521 WO2020182229A1 (zh) 2019-03-14 2020-04-30 一种融合蛋白及其制备利拉鲁肽中间体多肽的方法

Country Status (2)

Country Link
CN (2) CN109879970A (zh)
WO (1) WO2020182229A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114292338A (zh) * 2021-12-31 2022-04-08 南京汉欣医药科技有限公司 一种融合蛋白及其制备司美格鲁肽中间体多肽的方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109879970A (zh) * 2019-03-14 2019-06-14 美药星（南京）制药有限公司 一种融合蛋白及其制备利拉鲁肽中间体多肽的方法
CN110498849A (zh) * 2019-09-16 2019-11-26 南京迪维奥医药科技有限公司 一种索玛鲁肽主肽链及其制备方法
CN111072783B (zh) * 2019-12-27 2021-09-28 万新医药科技(苏州)有限公司 一种采用大肠杆菌表达串联序列制备glp-1或其类似物多肽的方法
CN113135990A (zh) * 2020-01-20 2021-07-20 宁波鲲鹏生物科技有限公司 利拉鲁肽衍生物及其制备方法
CN112522294B (zh) * 2020-12-24 2022-03-22 珠海冀百康生物科技有限公司 一种glp-1类似物的半重组制备方法
CN115873124A (zh) * 2021-09-29 2023-03-31 合肥天汇生物科技有限公司 Glp-1类似物的融合多肽
CN114790473A (zh) * 2021-11-08 2022-07-26 汉肽生物医药集团有限公司 一种利拉鲁肽融合蛋白在位酶切和纯化的方法
CN114457099B (zh) * 2021-12-18 2023-12-15 江苏阿尔法药业股份有限公司 一种索马鲁肽核心肽链的生物发酵制备方法
CN114933658B (zh) * 2022-04-24 2023-07-11 深圳市鹏泰生物科技有限公司 一种短肽元件及其应用方法
CN114807205B (zh) * 2022-06-29 2022-09-13 北京惠之衡生物科技有限公司 表达利拉鲁肽前体的重组工程菌及其构建方法和应用
CN115850385B (zh) * 2022-07-04 2023-08-11 北京惠之衡生物科技有限公司 一种促表达肽及其应用
CN115261399A (zh) * 2022-08-02 2022-11-01 态创生物科技(广州)有限公司 基于细菌展示和蛋白酶切割的寡肽表达和提纯方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1177928A (zh) * 1994-12-29 1998-04-01 生物技术通用公司 生产人胰岛素
CN108191981A (zh) * 2018-02-06 2018-06-22 美药星（南京）制药有限公司 一种利拉鲁肽中间体多肽的制备方法
CN109879970A (zh) * 2019-03-14 2019-06-14 美药星（南京）制药有限公司 一种融合蛋白及其制备利拉鲁肽中间体多肽的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001604A (en) * 1993-12-29 1999-12-14 Bio-Technology General Corp. Refolding of proinsulins without addition of reducing agents
CN104592381A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种利拉鲁肽中间体多肽的制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1177928A (zh) * 1994-12-29 1998-04-01 生物技术通用公司 生产人胰岛素
CN108191981A (zh) * 2018-02-06 2018-06-22 美药星（南京）制药有限公司 一种利拉鲁肽中间体多肽的制备方法
CN109879970A (zh) * 2019-03-14 2019-06-14 美药星（南京）制药有限公司 一种融合蛋白及其制备利拉鲁肽中间体多肽的方法
CN110128552A (zh) * 2019-03-14 2019-08-16 美药星（南京）制药有限公司 一种融合蛋白及其制备利拉鲁肽中间体多肽的方法

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114292338A (zh) * 2021-12-31 2022-04-08 南京汉欣医药科技有限公司 一种融合蛋白及其制备司美格鲁肽中间体多肽的方法
CN114292338B (zh) * 2021-12-31 2023-01-03 南京汉欣医药科技有限公司 一种融合蛋白及其制备司美格鲁肽中间体多肽的方法
WO2023125178A1 (zh) * 2021-12-31 2023-07-06 南京汉欣医药科技有限公司 一种融合蛋白及其制备司美格鲁肽中间体多肽的方法

Also Published As

Publication number Publication date
CN110128552B (zh) 2021-04-02
CN109879970A (zh) 2019-06-14
CN110128552A (zh) 2019-08-16

Similar Documents

Publication Publication Date Title
WO2020182229A1 (zh) 一种融合蛋白及其制备利拉鲁肽中间体多肽的方法
US10851146B2 (en) Method for preparing liraglutide intermediate polypeptide
WO2020259403A1 (zh) 重组串联融合蛋白制备目标多肽的方法
CN110724187B (zh) 一种高效表达利拉鲁肽前体的重组工程菌及其应用
JP4504014B2 (ja) インスリン分泌性ｇｌｐ−１（７−３６）ポリペプチドおよび／またはｇｌｐ−１類似体を生成する方法
CN102083855A (zh) 活性延长的新胰岛素类似物
CN113105536B (zh) 一种新甘精胰岛素原及其制备甘精胰岛素的方法
CN110498849A (zh) 一种索玛鲁肽主肽链及其制备方法
CN112584853B (zh) 一种新型门冬胰岛素原的结构和制备门冬胰岛素的方法
CN106434717A (zh) 一种生物合成制备人glp‑1多肽或其类似物的方法
WO2022012020A1 (zh) Glp-1类似物多肽的制备方法及在ⅱ型糖尿病中应用
CN107881187A (zh) 将大肠杆菌表达的融合蛋白转化为利拉鲁肽的制备方法及应用
CN113502296A (zh) 一种高表达司美鲁肽前体重组工程菌及其构建方法
WO2023125178A1 (zh) 一种融合蛋白及其制备司美格鲁肽中间体多肽的方法
CN102618552A (zh) 一种重组艾塞那肽的生产工艺
WO2020258372A1 (zh) 硫氧还蛋白突变体、其制备方法及其在重组融合蛋白生产中的应用
CN113105561B (zh) 一种双靶点融合蛋白的制备方法和应用
CN112522294B (zh) 一种glp-1类似物的半重组制备方法
CN106608915A (zh) Glp-1(7-37)多肽类似物
CN114933658B (zh) 一种短肽元件及其应用方法
AU2019218315A1 (en) Codon optimized precursor gene and signal peptide gene of human insulin analogue
CN102732549B (zh) 一种重组胰岛素样生长因子-i的制备方法
CN100535111C (zh) 一种制备重组Exendin-4多肽的新工艺
CN112574286A (zh) 多肽及其应用
WO2011063549A1 (zh) 长效exendin4的类似物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20770671

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20770671

Country of ref document: EP

Kind code of ref document: A1